With failed COVID shot still dragging on earnings, CureVac tries to turn page to next-gen mRNA tech

CureVac’s first-generation COVID vaccine—a shot that failed to reach anywhere near the high efficacy bar set by rivals—is continuing to drag on the German biotech’s earnings and is expected to negatively impact sales for the rest of the year.